This is the authors' abstract. We don't add key points for this paper.
Apply established and emerging cerebrospinal fluid (CSF) biomarkers to improve diagnostic accuracy and recognition of patients with potentially treatment-responsive causes of rapidly progressive dementia (RPD).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Day et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: